IP Library › Granted Patent US 12,240,815
Granted Patent B2
US 12,240,815 · App. 17/184,544 · Granted Mar 4, 2025

Potent and selective human neuronal nitric oxide synthase inhibitors

Inventors: Richard B. Silverman (Winnetka, IL); Ha T. Do (Evanston, IL)
Assignee: Northwestern University
C07D213/73C07D401/06C07D401/10C07D413/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,240,815
App. No.
17/184,544
Granted
Mar 4, 2025
Kind
B2
Abstract

Disclosed are 2-aminopyridine derivative compounds for use as inhibitors of nitric oxide synthase (NOS). In particular, the field of the invention relates to 2-aminopyridine derivative compounds for use as inhibitors of neuronal nitric oxide synthase (nNOS), which are formulated as pharmaceutical compositions for treating diseases and disorders associated with nNOS such as Alzheimer's, Parkinson's, and Huntington's diseases, and amyotrophic lateral sclerosis, cerebral palsy, stroke/ischemic brain damage, and migraine headaches.

Claims (31)

1. A compound of a Formula (I) or a salt or solvate thereof:

where X is hydrogen, C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, halogen, or haloalkyl,

represents a single, double, or triple bond;

Y is aryl substituted with halogen and a substituent having a formula —Z—R a ; or Y is 7-10 membered heteroaryl substituted at one or more ring positions with a substituent having a formula —Z—R a ; or Y has a formula —Z—R a ;

Z is selected from C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, and C 2 -C 6 -alkynyl;

R a is selected from alkylamino, dialkylamino, and a 4-6 membered heterocycle which contains at least one nitrogen atom and which heterocycle is optionally substituted at one or more positions with alkyl, alkoxy, or halogen; and

wherein if Y is aryl substituted with one halogen and one substituent having a formula —C 1 -C 6 -alkyl-R a , then R a is the 4-6 membered heterocycle which contains at least one nitrogen atom and which heterocycle is optionally substituted at one or more positions with alkyl, alkoxy, or halogen.

2. The compound of claim 1 , wherein R a is selected from pyrrolidinyl which optionally is substituted at one or more positions with alkyl or alkoxy or halogen, azetinyl which optionally is substituted at one or more positions with alkyl, morpholinyl optionally substituted at one or more position with alkyl, and piperazinyl optionally substituted at one or more positions with alkyl.

3. The compound of claim 1 of a Formula (Ia):

wherein R 2 , R 3 , R 4 , and R 6 , are each independently H or halogen; and

at least one of R 2 , R 3 , R 4 , and R 6 is halogen.

4. The compound of claim 3 , wherein R 3 is halogen.

5. The compound of claim 3 , wherein R 2 is halogen.

6. The compound of claim 3 , wherein R 2 is halogen and R 3 is halogen.

7. The compound of claim 1 , wherein Z is CH 2 .

8. The compound of claim 1 , wherein R is dimethylamino.

9. The compound of claim 1 of a Formula (IIb):

10. The compound of claim 1 of a formula:

11. The compound of claim 1 , wherein the compound has an effective permeability P e for the blood brain barrier of at least about 8×10 −6 cm/s.

12. The compound of claim 1 , wherein the compound has a selectivity for nNOS versus iNOS of at least about 30.

13. The compound of claim 1 , wherein the compound has a selectivity for nNOS versus eNOS of at least about 1000.

14. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

15. A method of treating a disease or disorder associated with nitric oxide synthase in a subject in need thereof, the method comprising administering to the subject an effective amount of the compound of claim 1 .

16. The method of claim 15 , wherein the disease or disorder is a neurodegenerative disease or disorder.

17. The method of claim 15 , wherein the disease or disorder is Alzheimer's disease.

18. The method of claim 15 , wherein the disease or disorder is Huntington's disease.

19. The method of claim 15 , wherein the disease or disorder is Parkinson's disease.

20. The method of claim 15 , wherein the disease or disorder is amyotrophic lateral sclerosis (ALS).

21. The method of claim 15 , wherein the disease or disorder is cerebral palsy.

22. The method of claim 15 , wherein the disease or disorder is a migraine headache.

23. A method of inhibiting nitric oxide synthase (NOS) in a cell, the method comprising contacting the cell with the compound of claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2021
From: SILVERMAN, RICHARD B.; DO, HA T.
To: NORTHWESTERN UNIVERSITY
Reel/Frame 056684/0326 →
Continuity (3)
Continuation PCTUS2020019466 · Feb 24, 2020
Provisional Application 62980735 · Feb 24, 2020
Related Publication 20210269400A1 · Sep 2, 2021
References Cited (92)
US 5972975A · Esser · 1999 [cited by examiner]
US 7317021B2 · Fuchss · 2008 [cited by examiner]
US 8735606B2 · Silverman · 2014 [cited by applicant]
US 8829187B1 · Silverman · 2014 [cited by applicant]
US 8932842B2 · Silverman · 2015 [cited by applicant]
US 9090589B2 · Silverman · 2015 [cited by applicant]
US 9120750B2 · Silverman · 2015 [cited by applicant]
US 9212144B2 · Silverman · 2015 [cited by applicant]
US 9212161B2 · Silverman · 2015 [cited by applicant]
US 9242957B2 · Silverman · 2016 [cited by applicant]
US 9416106B2 · Silverman · 2016 [cited by applicant]
US 9663468B2 · Silverman · 2017 [cited by applicant]
US 9682950B2 · Silverman · 2017 [cited by applicant]
US 9701661B2 · Silverman · 2017 [cited by applicant]
US 9732037B2 · Silverman · 2017 [cited by applicant]
US 9758507B2 · Silverman · 2017 [cited by applicant]
US 9765055B2 · Silverman · 2017 [cited by applicant]
US 9783500B2 · Silverman · 2017 [cited by applicant]
US 9878996B2 · Silverman · 2018 [cited by applicant]
US 9951014B2 · Silverman · 2018 [cited by applicant]
US 10167260B2 · Silverman · 2019 [cited by applicant]
US 10759791B2 · Silverman · 2020 [cited by applicant]
US 20130040359A1 · Silverman · 2013 [cited by applicant]
US 20140228578A1 · Silverman · 2014 [cited by applicant]
US 20140256016A1 · Silverman · 2014 [cited by applicant]
US 20150210644A1 · Silverman · 2015 [cited by applicant]
US 20150252020A1 · Silverman · 2015 [cited by applicant]
US 20160122302A1 · Silverman · 2016 [cited by applicant]
US 20160368877A1 · Silverman · 2016 [cited by applicant]
US 20170260165A1 · Silverman · 2017 [cited by applicant]
US 20170275278A1 · Silverman · 2017 [cited by applicant]
US 20170298021A1 · Silverman · 2017 [cited by applicant]
US 20200179368A1 · Silverman · 2020 [cited by applicant]
US 20200331910A1 · Silverman · 2020 [cited by applicant]
US 20200377481A1 · Silverman · 2020 [cited by applicant]
US 20210269400A1 · Silverman · 2021 [cited by applicant]
WO 2017214286 · 2017 [cited by applicant]
Cecil Textbook of Medicine, 20th edition (1996), vol. 2, pp. 2050-2057. [cited by examiner]
Cecil Textbook of Medicine, 20th edition (1996), vol. 2, pp. 1992-1996. [cited by examiner]
FDA mulls drug to slow late-stage Alzheimer's [online], [retrieved on Sep. 23, 2003]. Retrieved from the internet, URL;http;//www.cnn/com/2003/HEALTH/conditions/09/24/alzheimers.drug.ap/index.html>. [cited by examiner]
Winn, M. D. etal. Use of TLS parameters to model anisotropic displacements in macromolecular refinement. Acta Crystallographica Section D 2001, 57, 122-133. [cited by applicant]
Yung-Chi, C. et al. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (150) of an enzymatic reaction. Biochemical Pharmacology 1973, 22, 3099-3108. [cited by applicant]
Adams, P. D.; et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallographica Section D 2010, 66, 213-221. [cited by applicant]
Alderton, W. K.; et al. Nitric oxide synthases: structure, function and inhibition. Biochemical Journal 2001, 357, 593-615. [cited by applicant]
Banks, W. A. From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. Nature Reviews Drug Discovery 2016, 15, 275. [cited by applicant]
Barbanti, P. et al. Drugs targeting nitric oxide synthase for migraine treatment. Expert Opinion on Investigational Drugs 2014, 23, 1141-1148. [cited by applicant]
Battye, T. G. G. et al. iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM. Acta Crystallographica Section D: Biological Crystallography 2011, 67, 271-281. [cited by applicant]
Bolanos, J. P. et al. Nitric oxide-mediated mitochondrial damage in the brain: Mechanisms and implications for neurodegenerative diseases. Journal of Neurochemistry 1997, 68, 2227-2240. [cited by applicant]
Cinelli, M. A. et al. Nitrile in the Hole: Discovery of a Small Auxiliary Pocket in Neuronal Nitric Oxide Synthase Leading to the Development of Potent and Selective 2-Aminoquinoline Inhibitors. Journal of Medicinal Che… [cited by applicant]
Cinelli, M. A. et al. Phenyl Ether- and Aniline-Containing 2-Aminoquinolines as Potent and Selective Inhibitors of Neuronal Nitric Oxide Synthase. Journal of Medicinal Chemistry 2015, 58, 8694-8712. [cited by applicant]
De La Torre, J. C. et al. Evidence that Alzheimer's disease is a microvascular disorder: the role of constitutive nitric oxide. Brain Research Reviews 2000, 34, 119-136. [cited by applicant]
Di, L. et al. Demystifying Brain Penetration in Central Nervous System Drug Discovery. Journal of Medicinal Chemistry 2013, 56, 2-12. [cited by applicant]
Do et al., “Optimization of Blood-Brain Barrier Permeability with Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors Having a 2-Aminopyridine Scaffold,” J. Med. Chem. 2019, 62, 5, 2690-2707. [cited by applicant]
Do, H. T. et al. Improvement of Cell Permeability of Human Neuronal Nitric Oxide Synthase Inhibitors Using Potent and Selective 2-Aminopyridine-Based Scaffolds with a Fluorobenzene Linker. Journal of Medicinal Chemistry… [cited by applicant]
Drechsel, D. A. et al. Nitric oxide-mediated oxidative damage and the progressive demise of motor neurons in ALS. Neurotoxicity research 2012, 22, 251-264. [cited by applicant]
Emsley, P. et al. Coot: model-building tools for molecular graphics. Acta Crystallographica Section D 2004, 60, 2126-2132. [cited by applicant]
Evans, P. Scaling and assessment of data quality. Acta Crystallographica Section D 2006, 62, 72-82. [cited by applicant]
Feng, B. et al. In Vitro P-glycoprotein Assays to Predict the in Vivo Interactions of P-glycoprotein with Drugs in the Central Nervous System. Drug Metabolism and Disposition 2008, 36, 268-275. [cited by applicant]
Fischmann, T. O. et al. Structural characterization of nitric oxide synthase isoforms reveals striking active-site conservation. Nature Structural Biology 1999, 6, 233. [cited by applicant]
Fossetta, J. D. et al. Expression of human inducible nitric oxide synthase in [cited by applicant]
Garthwaite, J. et al. Nitric Oxide Signaling in the Central Nervous System. Annual Review of Physiology 1995, 57, 683-706. [cited by applicant]
Gribkoff, V. K. et al. The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes. Neuropharmacology 2017, 120, 11-19. [cited by applicant]
Hevel, J. M. et al. [25] Nitric oxide synthase assays. Methods in Enzymology 1994, 233, 250-258. [cited by applicant]
Hevel, J. M. et al. Purification of the inducible murine macrophage nitric oxide synthase. Identification as a flavoprotein. Journal of Biological Chemistry 1991, 266, 22789-91. [cited by applicant]
International Searching Authority. International Search Report and Written Opinion for application PCT/US2020/019466. Mailed on Nov. 19, 2020. 10 pages. [cited by applicant]
Ji, H. et al. Minimal Pharmacophoric Elements and Fragment Hopping, an Approach Directed at Molecular Diversity and Isozyme Selectivity. Design of Selective Neuronal Nitric Oxide Synthase Inhibitors. Journal of the Amer… [cited by applicant]
Kabsch, W. XDS. Acta Crystallographica Section D: Biological Crystallography 2010, 66, 125-132. [cited by applicant]
Kang, S. et al. 2-Aminopyridines with a Truncated Side Chain To Improve Human Neuronal Nitric Oxide Synthase Inhibitory Potency and Selectivity. Journal of Medicinal Chemistry 2015, 58, 5548-5560. [cited by applicant]
Leber, A. et al. Characterization of Recombinant Human Endothelial Nitric-oxide Synthase Purified from the Yeast Pichia pastoris. Journal of Biological Chemistry 1999, 274, 37658-37664. [cited by applicant]
Li, H. et al. Crystal Structures of Zinc-free and -bound Heme Domain of Human Inducible Nitric oxide Synthase: Implications for Dimer Stability and Comparison With Endothelial Nitric-Oxide Synthase. Journal of Biologica… [cited by applicant]
Li, H. et al. Electrostatic Control of Isoform Selective Inhibitor Binding in Nitric Oxide Synthase. Biochemistry 2016, 55, 3702-3707. [cited by applicant]
Li, H. et al. Structures of human constitutive nitric oxide synthases. Acta Crystallographica Section D 2014, 70, 2667-2674. [cited by applicant]
Liebschner, D. et al. Polder maps: improving OMIT maps by excluding bulk solvent. Acta Crystallographica. Section D, Structural Biology 2017, 73, 148-157. [cited by applicant]
Loscher, W. et al. Drug resistance in brain diseases and the role of drug efflux transporters. Nature Reviews Neuroscience 2005, 6, 591. [cited by applicant]
Maccallini, C. et al. Targeting neuronal nitric oxide synthase as a valuable strategy for the therapy of neurological disorders. Neural Regeneration Research 2016, 11, 1731-1734. [cited by applicant]
McCoy, A. J. et al. Phaser crystallographic software. Journal of Applied Crystallography 2007, 40, 658-674. [cited by applicant]
McPhillips, T. M. et al. Blu-Ice and the Distributed Control System: software for data acquisition and instrument control at macromolecular crystallography beamlines. Journal of Synchrotron Radiation 2002, 9, 401-406. [cited by applicant]
Moore, P. K. et al. Selective inhibitors of neuronal nitric oxide synthase—is no NOS really good NOS for the nervous system? Trends in Pharmacological Sciences 1997, 18, 204-211. [cited by applicant]
Mukherjee, P. et al. Development of nitric oxide synthase inhibitors for neurodegeneration and neuropathic pain. Chemical Society Reviews 2014, 43, 6814-6838. [cited by applicant]
Muller, J. et al. Tuning the predictive capacity of the PAMPA-BBB model. European Journal of Pharmaceutical Sciences 2015, 79, 53-60. [cited by applicant]
Muller, S. et al. An Improved One-pot Procedure for the Synthesis of Alkynes from Aldehydes. Synlett 1996, 1996, 521-522. [cited by applicant]
Murshudov, G. N. et al. Refinement of Macromolecular Structures by the Maximum-Likelihood Method. Acta Crystallographica Section D 1997, 53, 240-255. [cited by applicant]
Nutt, D. J. et al. CNS drug development in Europe—Past progress and future challenges. Neurobiology of Disease 2014, 61, 6-20. [cited by applicant]
Patil, A. G. et al. Validation of quinidine as a probe substrate for the in vitro P-gp inhibition assay in Caco-2 cell monolayer. European Journal of Drug Metabolism and Pharmacokinetics 2011, 36, 115. [cited by applicant]
Rankovic, Z. CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure. Journal of Medicinal Chemistry 2015, 58, 2584-2608. [cited by applicant]
Roman, L. J. et al. High-level expression of functional rat neuronal nitric oxide synthase in [cited by applicant]
Silverman, R. B. Design of Selective Neuronal Nitric Oxide Synthase Inhibitors for the Prevention and Treatment of Neurodegenerative Diseases. Accounts of Chemical Research 2009, 42, 439-451. [cited by applicant]
St. Jean, D. J. et al. Mitigating Heterocycle Metabolism in Drug Discovery. Journal of Medicinal Chemistry 2012, 55, 6002-6020. [cited by applicant]
Torreilles, F. et al. Neurodegenerative disorders: the role of peroxynitrite. Brain Research Reviews 1999, 30, 153-163. [cited by applicant]
Uehara, T. et al. S-Nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature 2006, 441, 513-517. [cited by applicant]
Wager, T. T. et al. Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties. ACS Chemical Neuroscience 2010, 1, 435-449. [cited by applicant]
Wang, H.-Y. et al. Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibition by Optimization of the 2- Aminopyridine-Based Scaffold with a Pyridine Linker. Journal of Medicinal Chemistry 2016, 59, 4913-4925. [cited by applicant]